鄧覓檢視原始碼討論檢視歷史
 |
鄧覓，男，北京大學基礎醫學院教授。
人物履歷
2007–2012 美國內布拉斯加大學醫學中心 博士
2012–2015 美國得克薩斯大學西南醫學中心 博士後
2015–2017 美國得克薩斯大學西南醫學中心 講師
2017–2020 美國得克薩斯大學西南醫學中心 助理教授
學術任職
2020–現在 北京大學國際癌症研究院/北京大學腫瘤醫院 研究員
2018–現在 Antibody Therapeutics 期刊編委/助理編輯
2020–現在 Translational Oncology 期刊編委
2021–現在 Frontiers in Immunology 期刊主題編輯
2021–現在 中華醫學會腫瘤學分會 第十二屆委員會青年學組成員
2021–現在 中國病理生理學會第九屆實驗血液學專業委員會血液免疫學組委員
2021–現在 中國人體健康科技促進會 淋巴瘤專業委員會常務委員
研究方向
我們長期以腫瘤免疫學為研究方向，主要以免疫細胞和腫瘤細胞為研究對象，致力於探索腫瘤細胞逃逸免疫監控的分子機制，利用細胞生物學、高通量多組學等方法和人源化動物模型，發現新的腫瘤免疫治療靶點，開發大分子抗體藥物和細胞治療技術。
1）探索腫瘤免疫微環境中免疫細胞與其他細胞之間的相互作用關係；
2）闡述免疫檢查點在腫瘤免疫微環境中的生物學功能和分子機制；
3）開發重大疾病的免疫治療的新藥物和新方法。
學術成果
論文
1. Yang T; Qian Y; Liang X, Wu J, Zou M, Deng M. (2022) LILRB4, an immune checkpoint on myeloid cells. Blood Sci . 4(2): 49-56.
2. Wu G, Xu Y, Schultz R, Chen H, Xie J, Deng M, Liu X, Gui X, John S, Lu Z, Arase H, Zhang N, An Z, Zhang CC. (2021) LILRB3 supports acute myeloid leukemia development and regulates T cell anti-tumor immune responses through the TRAF2-cFLIP-NF-kB signaling axis. Nat Cancer. 2:1170-84.
3. Gu Z, Liu Y, Zhang Y, Cao H, Lyu J, Wang X, Wylie A, Newkirk S, Jones A, Lee M, Botten G, Deng M, Dickerson K, Zhang CC, An W, Abrams J, Xu J. (2021) Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia. Nat Genet. 53(5):672-82.
4. Deng M, Chen H, Liu X, Huang R, He Y, Yoo B, Xie J, John S, Zhang N, An Z, Zhang CC. (2021) Leukocyte immunoglobulin-like receptor subfamily B (LILRB): therapeutic targets in cancer. Antib Ther . 4(1):16-33.
5. Anami Y, Deng M, Gui X, Yamaguchi A, Yamazaki C, Zhang N, Zhang CC, An Z, and Tsuchikama K. (2020) LILRB4-Targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 19：2330-2339.
6. Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. (2020) LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 17(3):272-282.
7. Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, He L, Huang F, Xu Y, Anami Y, Yu H, Yu C, Li L, Yuan Z, Xu X, Wang Q, Chai Y, Huang T, Shi Y, Tsuchikama K, Liao XC, Xia N, Gao GF, Zhang N, Zhang CC, An Z. (2019) Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T cell suppression and blocks AML development. Cancer Immunol Res. 7(8):1244-57.
8. Deng M. (2019) The approval of Sinitilimab for classical Hodgkin’s lymphoma: Views and Perspectives of anti-PD-1/PD-L1 antibodies in China. Antib Ther . 2(2): 54-55.
9. Deng M, Gui X, Kim J*, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen G-Q, Fu Y-X, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumor infiltration. Nature . 562(7728):605-9.
10. John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC. (2018) A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther . 26(10):2487-95.
11. Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. (2015) The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development. Nat Cell Biol . 17(5):665-77.
12. Deng M, Lu Z, Zheng J, Wan X, Chen X, Hirayasu K, Sun H, Lam Y, Chen L, Wang Q, Song C, Huang N, Gao GF, Jiang Y, Arase H, Zhang CC. (2014) A motif in LILRB2 critical for ANGPTL2 binding and activation. Blood . 124(6):924-35.
13. Yu X, Wang Y, Deng M, Li Y, Ruhn KA, Zhang CC, Hooper LV. (2014) The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. Elife . 3. doi: 10.7554/eLife.04406.
14. Yan Q, Gong L, Deng M, Zhang L, Sun S, Liu J, Ma H-L, Yuan D, Chen P-C, Hu X-H, Liu J-P, Qin J, Xiao L, Huang X-Q, Zhang J, Li DW-C. (2010). Sumoylation activates the transcriptional activity of p32 Pax-6, an important transcription factor for eye and brain development. Proc Natl Acad Sci USA. 107(49): 21034-39.
15. Deng M, Chen PC, Xie S, Zhao J, Gong L, Liu J, Zhang L, Sun S, Liu J, Ma H, Batra S, Li DW. (2010). The small heal shock protein alphaA-crystallin is expressed in pancreas and acts as negative regulator of carcinogenesis. Biochim Biophys Acta - Mol Basis Dis . 1802: 621-31.
16. Xiao L, Gong L, Yuan D, Deng M, Chen L, Zhang L, Yan Q, Liu J-P, Hu X, Sun S, Liu J, Ma H, Zheng C, Fu H, Chen P, Zhao J, Xie S, Zeng X, Zou L, Xiao Y-M, Liu W-B, Zhang J, Liu Y and Li D W-C. (2010). Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation . Cell Death & Differ . 17(9): 1448-62.
專利
1. Zhang CC, Deng M, An Z, Xiong W, Zhang N, Zheng, J. (2016) Anti-lilrb Antibodies and their use in detecting and treating cancer. (Patent number: PCT/US2016/020838)
2. Bernstein ID, Zhang CC, Deng M, Lu Z, Zheng J. (2017) Lilrb2 and notch-mediated expansion of hematopoietic precursor cells. (Patent number: PCT/US2015/031959)
3. Zhang CC, Liu Y, Zheng J, Deng M, Chen C, Liu J. (2017) Novel compounds supports hematopoietic stem cells and red blood cells. (Patent number: PCT/US2015/030352)
4. Zhang CC, An Z, Zhang N, Deng M, Kim, J, Gui X. (2018) Methods for identifying lilrb-blocking antibodies. (Patent number: PCT/US2017/044171)
5. Liao X, Liu Q, An Z, Zhang N, Gui X, Zhang CC, Deng M, Xie J. (2018) Anti-lair1 antibodies and their uses. (Patent number: PCT/US2018/012040)
6. Zhang CC, John S, Chen H, Deng M, Gui X, Zhang N, An Z. (2019) Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer. (Patent number: PCT/US2018/059362)
7. An Z, Zhang CC, Zhang N, Gui X, Deng M, Huang T, Liu Q, Liao X. (2020) Novel LILRB4 antibodies and uses thereof. (Patent number: PCT/US2019/050727)
8. Zhang CC, Zhang N, An Z, Wu G, Kim J, Chen H, Deng M, Huang R. (2021) Antibodies against LILRB3 for therapeutic and diagnostic uses. (Patent number: PCT/US2021/061630)[1]